EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HER2-Mutant Advanced and/or Metastatic Non–Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes

Sarah Waliany, Joel W Neal, Nicole Engel-Nitz, Clara Lam, Feng Lin, Leah Park, Lisa Le, Misako Nagasaka

Clinical Lung Cancer · 2024-06 · 25 (4) · 319-328.e1

DOI: 10.1016/j.cllc.2024.01.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024-06. Verfasst von Sarah Waliany und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Electronic Health Records. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca, Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Real-world data for advanced/metastatic non-small-cell lung cancer (NSCLC) with mutations in human epidermal growth factor 2 (HER2) are scarce. We aimed to assess treatment patterns and outcomes among patients with HER2-mutant advanced/metastatic NSCLC. PATIENTS AND METHODS: This retrospective nationwide electronic health record study evaluated patient characteristics, treatment patterns, treatment duration, and overall survival for adults with HER2-mutant advanced/metastatic NSCLC without epidermal growth factor receptor mutation. RESULTS: Of 55 included patients, median (quartile 1 [Q1]-quartile 3 [Q3]) age was 63.0 (58.0-72.0) years, 42 (76%) were women, and 39 (71%) were current/former smokers. In first-line therapy, 14 regimens were used for median (Q1-Q3) duration of 3.1 (2.4-6.2) months, with most patients (n = 39, 71%) receiving platinum-based chemotherapy alone or in combination with other agents. Median (95% CI) overall survival from first-line treatment initiation was 19.0 (12.2-not estimable) months, with no significant association with age, sex, or smoking status. Thirty-five (64%) patients received second-line therapy for median (Q1-Q3) duration of 3.3 (2.0-5.2) months. Fourteen second-line regimens were used; most commonly immunotherapy alone or in combination with other agents (n = 16, 46%). Sixteen (46%) patients received third-line therapy for median (Q1-Q3) duration of 1.9 (1.3-2.7) months. Nine third-line regimens were used, with 7 (44%) patients receiving HER2-directed agents. CONCLUSION: First- and second-line treatments for HER2-mutant NSCLC varied widely and treatment duration was short. The approval of trastuzumab deruxtecan for NSCLC supports wider HER2 testing to identify eligible patients for HER2-directed therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsErb-b2 Receptor Tyrosine KinasesElectronic Health RecordsMutationHumansFemaleMaleMiddle AgedAgedRetrospective StudiesUnited StatesPractice Patterns, Physicians'Treatment OutcomeDatabases, FactualAntineoplastic Combined Chemotherapy ProtocolsNeoplasm MetastasisSurvival Rate

Stichwörter der Autor:innen

ChemotherapyHuman epidermal growth factor 2 (HER2)Monoclonal antibodiesTargeted mutationsnon-small cell lung cancer (NSCLC)

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.
  • Stanford University Medical Center, Stanford, CA.
  • Optum Life Sciences, Eden Prairie, MN.
  • AstraZeneca Pharmaceuticals LP, Gaithersburg, MD.
  • Daiichi Sankyo, Inc., Basking Ridge, NJ.
  • University of California Irvine School of Medicine, Orange, CA. Electronic address: nagasakm@hs.uci.edu.

Förderung

  • AstraZeneca
  • Daiichi-Sankyo

Zitieren

APA

Waliany, S., Neal, J. W., Engel-Nitz, N., Lam, C., Lin, F., Park, L., Le, L., & Nagasaka, M. (2024). HER2-Mutant Advanced and/or Metastatic Non–Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes. Clinical Lung Cancer, 25(4), 319-328.e1. https://doi.org/10.1016/j.cllc.2024.01.002

Vancouver

Waliany S, Neal JW, Engel-Nitz N, Lam C, Lin F, Park L, et al. HER2-Mutant Advanced and/or Metastatic Non–Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes. Clinical Lung Cancer. 2024;25(4):319-328.e1. doi:10.1016/j.cllc.2024.01.002

BibTeX
@article{Waliany2024,
  author = {Waliany, Sarah and Neal, Joel W and Engel-Nitz, Nicole and Lam, Clara and Lin, Feng and Park, Leah and Le, Lisa and Nagasaka, Misako},
  title = {HER2-Mutant Advanced and/or Metastatic Non–Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes},
  journal = {Clinical Lung Cancer},
  year = {2024},
  volume = {25},
  number = {4},
  pages = {319--328.e1},
  doi = {10.1016/j.cllc.2024.01.002}
}
Kostenlos starten →